MAFLD: What Is It?

Houston Methodist

D. Victor

Current Treatment of Metabolic Dysfunction Associated with Steatotic…

Indiana University School of Medicine Division of Gastroenterology and Hepatology

N. Samala

Best Practices In Managing NAFLD / NASH

MedNews Week

D. Bernstein

The Fatty Liver Disease Epidemic

UPMC

M. Klinge

Using Resmetirom (THR-β Agonist) in Your Practice for MASH

Scripps Health

J. Gutierrez

Heart and Liver Interactions

Houston Methodist DeBakey Heart and Vascular Center

S. Adeel Ahsan

Fatty Liver Disease: Evaluation in the Primary Care Setting

Houston Methodist

D. W. Victor III

NASH Update 2023

Icahn School of Medicine at Mount Sinai

M. B. Bansal

Update on Hepatology Literature

UCLA Health

J. Benhammou, C. Wong

Cutting Edge Diagnostics and Treatment for NAFLD

Northwestern Medicine Gastroenterology

M. E. Rinella, L. Van Wagner

The Evolving Landscape of Non-Alcoholic Fatty Liver Disease (NAFLD) …

Cardiometabolic Health Congress (CMHC)

K. Cusi

Fatty Liver Disease: When to Refer?

Yale School of Medicine

NAFLD: Updates in Management

UChicago Medicine

M. E. Rinella

New Treatments for Steatotic Liver Disease (SLD): Are We There Yet?

University of Miami

S. A. Harrison

Updates on Management of NASH

Pennsylvania Society of Gastroenterology

T. Singh

Non-Alcoholic Fatty Liver Disease: Where Are We in 2023?

Houston Methodist

N. Gunn

Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease

Scripps Health

J. Au

Treating NASH 2023: Current and Near Future Treatments

UCLA Health

J. Singh

Advances in Management of Metabolic Dysfunction Associated Steatohep…

Keck School of Medicine of USC

M. E. Rinella

Liver Fat, Iron, Fibrosis, (and T1): Quantitative MRI in Chronic Liv…

UCSF School of Medicine

M. A. Ohliger